Davis, California – New UC Davis research shows that men with an FMR1 premutation who experienced reduced executive function were at higher likelihood of developing fragile X-associated tremor/ataxia syndrome (FXTAS). FXTAS is a progressive genetic condition that causes movement issues and cognitive decline. These findings, published in the journal Movement...
Latest News
Portland, OR – New research from Oregon Health & Science University suggests that people with multiple sclerosis, or MS, could benefit from a low-fat diet to improve the fatigue that’s a debilitating, and often-underappreciated, symptom of the condition. The study, published online Wednesday in the Multiple Sclerosis Journal, is the latest in...
Saint Louis, Missouri – In Alzheimer’s disease and related dementias, cognitive decline is driven by the overaccumulation of a normal brain protein known as tau. Wherever tau builds up, nearby brain tissue starts to degenerate and die. Now, researchers at Washington University School of Medicine in St. Louis have found...
Charleston, SC – A new compound developed by researchers at MUSC Hollings Cancer Center shows promise in overcoming chemotherapy resistance in triple-negative breast cancer – and could potentially be applied to fibrotic conditions like liver fibrosis or pulmonary fibrosis. At the center of this work is preventing the protein lysyl...
New Orleans, LA – Research led by Ashok Aiyar, PhD, Associate Professor of Microbiology at LSU Health Sciences Center New Orleans, showing that a single gene can control growth in cancers related to the Epstein-Barr virus and that existing therapeutics can inactivate it, will be published in the June 12,...
NEW YORK, NY – A Ludwig Cancer Research study has discovered how a lipid molecule found at high levels within tumors undermines the anti-cancer immune response and compromises a recently approved immunotherapy known as adoptive cell therapy (ACT) using tumor infiltrating lymphocytes, or TIL-ACT. In this individualized cell therapy, TILs—CD8+...
Barcelona, Spain – Pau Gorostiza, an ICREA research professor and principal investigator of the Nanoprobes and Nanoswitches group at the Institute for Bioengineering of Catalonia (IBEC) and CIBER-BBN, is set to coordinate the PHOTOTHERAPORT project, which is funded by the prestigious Pathfinder Open programme of the European Innovation Council (EIC)....
AUSTIN, Texas — Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today announced that it has launched two new cystic fibrosis (CF) tests in Europe, the xTAG® Cystic Fibrosis 39 Kit v2 and xTAG® Cystic Fibrosis 71 Kit v2, as CE IVD Marked products under the European Directive...
SEATTLE, WA — LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the initiation of the largest PBM trial ever conducted in patients with dry age-related macular degeneration (AMD). A global registry data collection from patients treated with PBM using the Valeda®...
SEATTLE, WA — LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced an update on the regulatory status of the Valeda® Light Delivery System. Following feedback from the FDA, a De Novo request to reclassify the Valeda Light Delivery System as a...